Clarifying eligibility for origin claims in the Complementary Medicines Sector

Closed 30 Oct 2019

Opened 3 Oct 2019

Published Responses

View submitted responses where consent has been given to publish the response.

Overview

In February 2017 amendments were made to the Country of Origin Labelling (CoOL) laws that changed the basis for being eligible to make 'made in Australia' claims, and subsequently access the Australian Made, Australian grown (AMAG) logo.

The CoOL law amendments focused on the food industry and is mandatory for priority-foods. However, all other products and goods that wish to make an AMAG claim are also bound by the CoOL laws.

The complementary medicines sector has advised the government that many of their products are no longer eligible to use the AMAG logo, which will potentially effect the growth of the sector.  

Regulation Impact Statement

This Consultation Regulation Impact Statement (RIS) discusses various options to assist the complementary medicines sector to regain access to the AMAG logo.

We will use the feedback obtained through this RIS to assist the government to make a decision that is in the best interest of all stakeholders.

What Happens Next

Comments on the Consultation Regulatory Impact Statement for origin claims in the Complementary Medicines Sector are now closed.

We are reviewing and analysing the submissions we received.

This feedback will inform consultation with the Commonwealth, state and territory governments, which will inform the Decision RIS.

Audiences

  • Consumers
  • State, territory or local government
  • Complementary medicines businesses
  • Supply chain and industry representatives
  • Business
  • Users of the AMAG logo
  • Interest in the AMAG logo
  • Commonwealth agencies

Interests

  • Australian Made Australian Grown Logo
  • Country of Origin Labelling
  • Complementary Medicines
  • Safe Harbour Defences substantial transformation test